Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

Summary

This phase II trial studies how well cabozantinib-s-malate works in treating younger patients with sarcomas, Wilms tumor, or other rare tumors that have come back, do not respond to therapy, or are newly diagnosed. Cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for tumor growth and tumor blood vessel growth.

Conditions

• Adrenal Cortical Carcinoma
• Alveolar Soft Part Sarcoma
• Central Nervous System Neoplasm
• Childhood Clear Cell Sarcoma of Soft Tissue
• Clear Cell Sarcoma of Soft Tissue
• Ewing Sarcoma
• Hepatoblastoma
• Hepatocellular Carcinoma
• Osteosarcoma
• Recurrent Adrenal Cortical Carcinoma
• Recurrent Alveolar Soft Part Sarcoma
• Recurrent Clear Cell Sarcoma of Soft Tissue
• Recurrent Ewing Sarcoma
• Recurrent Hepatoblastoma
• Recurrent Hepatocellular Carcinoma
• Recurrent Kidney Wilms Tumor
• Recurrent Malignant Solid Neoplasm
• Recurrent Osteosarcoma
• Recurrent Primary Malignant Central Nervous System Neoplasm
• Recurrent Renal Cell Carcinoma
• Recurrent Rhabdomyosarcoma
• Recurrent Soft Tissue Sarcoma
• Recurrent Thyroid Gland Medullary Carcinoma
• Refractory Adrenal Cortical Carcinoma
• Refractory Alveolar Soft Part Sarcoma
• Refractory Clear Cell Sarcoma of Soft Tissue
• Refractory Ewing Sarcoma
• Refractory Hepatoblastoma
• Refractory Hepatocellular Carcinoma
• Refractory Malignant Solid Neoplasm
• Refractory Osteosarcoma
• Refractory Primary Central Nervous System Neoplasm
• Refractory Primary Malignant Central Nervous System Neoplasm
• Refractory Renal Cell Carcinoma
• Refractory Rhabdomyosarcoma
• Refractory Soft Tissue Sarcoma
• Refractory Thyroid Gland Medullary Carcinoma
• Refractory Wilms Tumor
• Renal Cell Carcinoma
• Rhabdomyosarcoma
• Soft Tissue Sarcoma
• Solid Neoplasm
• Thyroid Gland Medullary Carcinoma
• Wilms Tumor

Interventions

DRUG

Cabozantinib

Given PO

DRUG

Cabozantinib S-malate

Given PO Note: Capsule formulation (Cometriq) not used in this trial.

OTHER

Pharmacological Study

Correlative studies

Sponsors & Collaborators

• National Cancer Institute (NCI)

  lead NIH

Principal Investigators

• Srivandana Akshintala · Children's Oncology Group

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

2 Years

Max Age

30 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2017-05-18

Primary Completion

2021-06-30

Completion

2026-06-27

FDA Drug

Yes

Countries

• United States

Study Locations